- Pfizer stock slid on mixed obesity drug trial results.
- Earnings topped forecasts, but COVID-related sales kept falling.
- Investors await late-stage data to gauge long-term growth.
Pfizer Inc. (NYSE: PFE) saw its stock slide in recent trading as investors weighed mixed clinical data from its obesity drug program against a solid quarterly earnings beat and broader challenges in its legacy businesses.
Shares of Pfizer dipped roughly 3% during Monday’s session, closing lower amid broader market volatility and sector rotation. The weakness came despite the company reporting stronger-than-expected results for the fourth quarter of 2025. (Reuters)
Pfizer released mid-stage trial results for its obesity drug candidate PF-3944, acquired through its $10 billion Metsera acquisition. The data showed up to 12.3% mean weight loss at 28 weeks in adults without diabetes and continued progress when patients switched from weekly to monthly dosing — a potential convenience edge over weekly rivals.
Looking ahead, investors will track full Phase 3 data for PF-3944 and additional pipeline readouts throughout 2026. Detailed results from obesity trials and presentations at major conferences — including the American Diabetes Association Scientific Sessions in June — could be key catalysts. Regulatory milestones and outcomes from the broader obesity drug program will also be critical in shaping sentiment.(Investing)
Despite these topline results, sentiment was muted: roughly 10% of patients discontinued treatment due to side effects, and analysts noted that efficacy appeared slightly below that of Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy, established GLP-1 therapies. The mixed clinical readout contributed to selling pressure on Pfizer shares.
While Pfizer’s recent earnings beat offers short-term reassurance, the stock’s near-term performance reflects investor caution over its obesity drug prospects and broader revenue headwinds. The company’s success in navigating competitive pressures and translating pipeline potential into future growth will be central to its valuation in the months ahead.(MarketWatch)
On the fundamental front, Pfizer reported Q4 2025 revenue of about $17.6 billion and adjusted EPS of $0.66, both beating Wall Street forecasts. However, total revenues showed a modest decline year-over-year, largely driven by waning demand for COVID-19 products such as Comirnaty and Paxlovid.
The company reaffirmed its 2026 guidance — projecting $59.5 billion–$62.5 billion in revenue and $2.80–$3.00 in adjusted EPS — even as analysts pointed to headwinds from declining COVID-related sales and impending patent expirations on key drugs.(Nasdaq)
Analysts described the earnings beat as a positive short-term signal but noted structural challenges ahead. “The PF-3944 data shows promise but will need further evidence to rival incumbents,” one healthcare strategist said, emphasizing that investors are watching both safety and efficacy closely. Others highlighted Pfizer’s broad pipeline and cost-management initiatives as potential offsets to near-term pressure.
Pfizer’s executive leadership stressed the importance of diversifying beyond COVID-era products, with strategic investments in obesity, oncology and immunology programs expected to drive longer-term growth.(Barron’s)